Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Why Codiak BioSciences Shares Are Nosediving During Monday's After-Hours Session

Published 12/09/2022, 22:42
Updated 12/09/2022, 23:40
© Reuters.  Why Codiak BioSciences Shares Are Nosediving During Monday's After-Hours Session

Codiak BioSciences Inc (NASDAQ: CDAK) shares are trading lower by 21.6% to $1.31 during Monday's after-hours session after the company proposed a public offering of common stock and warrants. No size was disclosed.

What Else?

Codiak intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock and warrants to purchase shares of common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions.

All the securities to be sold in the proposed offering will be sold by Codiak. The offering is subject to market and other conditions, and Codiak BioSciences says there can be no assurances as to whether or when the offering may be completed, or as to the actual size and terms of the offering.

According to data from Benzinga Pro, Codiak BioSciences has a 52-week high of $19.99 and a 52-week low of $1.67.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.